The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for […]readmore
Tags : Organicell
Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem BioNTech […]readmore
Shots: The company reported the results of an expanded access trial for Zofin in patients with COVID-19 which was conducted in Houston, TX The trial met EPs for safety & […]readmore
In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. […]readmore
BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority […]readmore
Shots: The company reported the positive results of the initial trial for Zofin in the first 10 COVID-19 patients treated with Zofin in India. The trial is being conducted with […]readmore